Back to Insider Trading View Full Company Profile

BEAM

UNKNOWN

Beam Therapeutics Inc.

CIK: 0001745999

Strong Sell (90% confidence)

Last activity: 2 weeks ago

Financial Metrics

As of Dec 31, 2022 (10-K)

Insider Roster (4 total, 4 active)

Insider Buys Sells Net Value Holdings
Evans John M.
CEO
0 4 -$1.44M
989,573 shares
$27.98M
Bellon Christine
Chief Legal Officer
0 5 -$725K
95,667 shares
$3.25M
Cavanagh Bethany J
SVP, Finance and Treasurer
0 2 -$308K
34,813 shares
$1.22M
Emany Sravan Kumar
Chief Financial Officer
0 1 -$171K
73,706 shares
$2.00M

Recent Transactions

SELL Evans John M. (CEO)

22,094 shares @ $28.27

$625K

Jan 30, 2026

Conviction: | View SEC Filing →
SELL Evans John M. (CEO)

2,906 shares @ $29.00

$84K

Jan 30, 2026

Conviction: | View SEC Filing →
SELL Evans John M. (CEO)

16,333 shares @ $29.19

$477K

Jan 29, 2026

Conviction: | View SEC Filing →
SELL Evans John M. (CEO)

8,667 shares @ $29.74

$258K

Jan 29, 2026

Conviction: | View SEC Filing →
SELL Cavanagh Bethany J (SVP, Finance and Treasurer)

6,198 shares @ $35.00

$217K

Jan 22, 2026

Conviction: | View SEC Filing →
SELL Bellon Christine (Chief Legal Officer)

1,371 shares @ $34.00

$47K

Jan 22, 2026

Conviction: | View SEC Filing →
SELL Cavanagh Bethany J (SVP, Finance and Treasurer)

3,034 shares @ $30.12

$91K

Jan 20, 2026

Conviction: | View SEC Filing →
SELL Bellon Christine (Chief Legal Officer)

15,959 shares @ $34.72

$554K

Jan 15, 2026

Conviction: | View SEC Filing →
SELL Bellon Christine (Chief Legal Officer)

2,111 shares @ $33.62

$71K

Jan 15, 2026

Conviction: | View SEC Filing →
SELL Bellon Christine (Chief Legal Officer)

559 shares @ $35.40

$20K

Jan 15, 2026

Conviction: | View SEC Filing →
SELL Emany Sravan Kumar (Chief Financial Officer)

6,294 shares @ $27.10

$171K

Dec 31, 2025

Conviction: | View SEC Filing →
SELL Bellon Christine (Chief Legal Officer)

1,254 shares @ $27.10

$34K

Dec 31, 2025

Conviction: | View SEC Filing →

⚠️ Important Disclaimer

• This is AI-generated analysis for educational purposes only, not financial advice.

• Insider trading data is derived from SEC Form 4 filings and may contain errors.

• Always conduct your own research and consult qualified financial advisors before making investment decisions.